National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Hospital acquired Candida infection is a major cause of morbidity and mortality especially in critically ill and immunocompromised patients. Therefore, an accurate and early identification is necessary for the management of patients. The aim of our study was rapid identification of Candida species and their antifungal susceptibility testing (AST) by VITEK 2 system in hospital acquired fungal infections. A total of 50 Candida isolates were identified by both conventional methods and by Vitek-2 system. Antifungal susceptibility of each isolate was determined by broth microdilution method and Vitek-2 system. Out of these 50 Candida isolates, C. albicans (n = 29) were most commonly isolated, followed by C. tropicalis (n = 9), C. krusei (n = 6), C. glabrata (n = 4), and C. parapsilosis (n = 2). C. albicans, C. tropicalis and C. krusei showed resistance to Flucytosine. C. albicans and C. glabrata showed resistance to Voriconazole. C. krusei showed resistance to Amphotericin B. All the correlation coefficient indices were statistically significant between Vitek-2 system and broth microdilution method in antifungal susceptibility testing of different Candida species. Sensitivity and specificity of Vitek2 system method in antifungal susceptibility testing for Flocytosine were 84%, 86% respectively, for Voriconazole were 94%, 96% respectively, and for Amphotericin B were 96%, 98% respectively. Our study revealed that Vitek-2 system reduces the period required for identification and antifungal susceptibility of Candida species. So, Vitek-2 system appeared to be a rapid reliable method for identification and AST for the Candida species to prescribe appropriate antifungal agents for early and better management of fungal infections especially in critically ill and immunosuppressed patients.
Citations |
 |
 |
 |
 |
